A Phase 1 open-label study to assess the safety, pharmacokinetics and anti-tumor activity of oral HP518 in patients with metastatic castration-resistant prostate cancer

  • Gurney, Howard (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)

Project: Research

Project Details

AcronymHP518-CS-001
StatusActive
Effective start/end date17/01/22 → 13/12/26